Cargando…

Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Who Fast During Ramadan in The Gulf Region: A Subgroup Analysis of the Real-World ORION Study

INTRODUCTION: To evaluate the safety and effectiveness of insulin glargine 300 U/mL (Gla-300) in people with type 2 diabetes mellitus (T2DM) in the Gulf region who fast during Ramadan. METHODS: ORION was a real-world, prospective, observational study in people with T2DM treated with Gla-300 during p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malik, Rayaz A., Elhadd, Tarik, Alattar, Abdulnabi, Al Shaikh, Abdulrahman, Al Randi, Muneera, Arora, Ravi, Al-Sifri, Saud, Akil, Yasser, Magdy, Amr, Naqvi, Mubarak, Hassanein, Mohamed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934889/ https://www.ncbi.nlm.nih.gov/pubmed/35239165 http://dx.doi.org/10.1007/s13300-022-01225-z

Ejemplares similares

SUN-LB126 Real-World Safety and Effectiveness of Insulin Glargine 300 U/ML (Gla-300) in People With Type 2 Diabetes Who Fast During Ramadan
por: Hassanein, Mohamed, et al.
Publicado: (2020)

Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan
por: Al Sifri, Saud
Publicado: (2012)

Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence
por: Al Sifri, Saud, et al.
Publicado: (2016)

A Real-World Observational Study of Gla-300 in Adults with Type 2 Diabetes Who Fast During Ramadan in the South Asia Region: A Subgroup Analysis of the ORION Study
por: Hassanein, Mohamed, et al.
Publicado: (2022)

Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies
por: Hassanein, Mohamed, et al.
Publicado: (2022)

Orion
por: Glass, Philip, et al.
Publicado: (2005)

Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11
por: Koenig, Wolfgang, et al.
Publicado: (2023)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Real-World Safety and Effectiveness of iGlarLixi in People With Type 2 Diabetes who Fast During Ramadan: Results From Wave 1 of the SOLIRAM Study
por: Hassanein, Mohamed, et al.
Publicado: (2021)

Descriptive Regional Subanalysis of a Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide MR During Fasting: DIA-RAMADAN
por: Hassanein, Mohamed, et al.
Publicado: (2021)

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
por: Galstyan, Gagik R., et al.
Publicado: (2022)

Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas
por: Al-Saleh, Yousef, et al.
Publicado: (2021)

Correction to: Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas
por: Al-Saleh, Yousef, et al.
Publicado: (2021)

Evaluation of Patient Reported Satisfaction and Clinical Efficacy of Insulin Glargine 300 U/mL Versus 100 U/mL in Patients With Type 1 Diabetes Using Flash Glucose Monitoring System
por: Al Hayek, Ayman Abdullah, et al.
Publicado: (2022)

Prevalence and risk factors for diabetic peripheral neuropathy, neuropathic pain and foot ulceration in the Arabian Gulf region
por: Ponirakis, Georgios, et al.
Publicado: (2022)

Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
por: Kovatchev, Boris, et al.
Publicado: (2020)

Comprehensive care for patients with diabetes in Ramadan: A module for pharmacy students and pharmacists
por: Al Rifai, Lina Abdallah, et al.
Publicado: (2022)

ORION: An Advanced Accelerator Facility at SLAC
por: Palmer, D T, et al.
Publicado: (2001)

International Workshop on the Orion Complex Revisited
por: McCaughrean, M J, et al.
Publicado: (1997)

Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
por: Yu, Neng Chun
Publicado: (2019)

Recommendations for Management of Diabetes During Ramadan: Update 2010
por: Al-Arouj, Monira, et al.
Publicado: (2010)

SUN-160 Insulin Glargine Time of Injection during Fasting Ramadan in Patients with Type 1 Diabetes
por: Alamoudi, Reem, et al.
Publicado: (2019)

A content analysis of food advertising in Arab Gulf countries during Ramadan
por: Alyousif, Zainab, et al.
Publicado: (2019)

SolarWinds Orion network performance monitor
por: Dissmeyer, Joe
Publicado: (2013)

ORION-the Omega Remote Interactive On-line System
por: Russell, R D, et al.
Publicado: (1974)

ORION - the OMEGA Remote Interactive On-line System
por: Russell, R D, et al.
Publicado: (1973)

Dataset of experimental measurements for the Orion beam structure()
por: Teloli, Rafael de Oliveira, et al.
Publicado: (2021)

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
por: Home, Philip D., et al.
Publicado: (2017)

Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis
por: Nakanishi, Shuhei, et al.
Publicado: (2018)

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
por: Bolli, G B, et al.
Publicado: (2015)

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
por: Ritzel, R, et al.
Publicado: (2015)

Ramadan fasting outcome among high-risk patients
por: Baynouna AlKetbi, Latifa, et al.
Publicado: (2022)

Utilization and cost of drugs for diabetes and its comorbidities and complications in Kuwait
por: Alowayesh, Maryam S., et al.
Publicado: (2022)

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml
por: Becker, R H A, et al.
Publicado: (2015)

Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives
por: de Galan, Bastiaan E
Publicado: (2016)

Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
por: Lindauer, Klaus, et al.
Publicado: (2019)

Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
por: Maffeis, Claudio, et al.
Publicado: (2022)

Giant star in orion may turn into a supernova
por: Browne, M W
Publicado: (1998)

The Orion Project Workshop : an Advanced Accelerator Research Facility
por: Collective
Publicado: (2000)

The orion complex a case study of interstellar matter
por: Goudis, C
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_h7b3eg85rba3urg67co0ssra9q